Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Smoking Cessation 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hepatitis B 1Hematuria 1Fatigue 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Letrozole 221Capecitabine 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 132Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × Urinalysis × Clear all
NCT00519168 2017-10-06

Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival

Stanford University

Completed
141 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡